CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: The residual (TCR-Vβ−) CD8+ T-cell populations were phenotypically similar in T-LGLL and dasatinib-treated CML patients, mirroring the subset distribution normally observed in healthy donor PBMCs (Fig. 2C, right panel).